Physician profile
Andrew C Bishop
NPI 1881702710
$6,155.08
in general payments reported to CMS, 2019-2025
30 companies · $854 in 2025
The $854 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $337 · 2021: $1,514 · 2022: $1,077 · 2023: $1,239 · 2024: $797 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,659 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.46 |
| Education | $230.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $990.56 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $805.79 | 2021-2025 | Ingrezza |
| Abbvie INC. | $574.46 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $573.97 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $435.06 | 2020-2024 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $403.59 | 2022-2025 | Sunosi, Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $363.73 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $328.48 | 2020-2024 | Fanapt |
| Janssen Pharmaceuticals, INC | $270.85 | 2019-2020 | |
| Alkermes, INC. | $215.43 | 2021-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $213.06 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $196.72 | 2020-2021 | |
| Eisai INC. | $109.28 | 2021 | |
| Biogen, INC. | $89.39 | 2023 | |
| Idorsia Pharmaceuticals US INC | $80.08 | 2023-2024 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $58.53 | 2023-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $58.08 | 2023 | Dyanavel Xr |
| Neuronetics, INC. | $52.12 | 2022-2023 | Neurostar Tms Therapy System |
| Allergan, INC. | $41.16 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $39.68 | 2021 | |
| Corium, LLC | $37.00 | 2023 | Azstarys |
| Livanova USA, INC. | $35.45 | 2020-2022 | |
| Kerecis Limited | $33.56 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $24.19 | 2022 | |
| Neos Therapeutics, LP | $23.16 | 2024 | Adzenys Xr-Odt |
| Indivior INC. | $22.45 | 2023 | Perseris |
| Novo Nordisk INC | $19.72 | 2025 | Ozempic, Rybelsus |
| Bausch Health US, LLC | $17.54 | 2022 | |
| Shire North American Group INC | $14.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.